INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION. EIC. Published online October 20, 2025:342-356. Accessed February 20, 2026. https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073